{
    "root": "2fc378a4-679e-45d4-e063-6394a90ae2af",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mirabegron",
    "value": "20250307",
    "ingredients": [
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYETHYLENE OXIDE 200000",
            "code": "11628IH70O",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25741"
        },
        {
            "name": "POLYETHYLENE OXIDE 2000000",
            "code": "5K3991GVWI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25741"
        },
        {
            "name": "MIRABEGRON",
            "code": "MVR3JL3B2V",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_65349"
        }
    ],
    "indications": {
        "text": "mirabegron extended-release tablets beta-3 adrenergic agonist indicated treatment : overactive bladder ( oab ) adult patients symptoms urge urinary incontinence , urgency , urinary frequency . ( 1.1 ) neurogenic detrusor overactivity ( ndo ) pediatric patients aged 3 years older weighing 35 kg . ( 1.2 )",
        "doid_entities": [
            {
                "text": "overactive bladder (DOID:0070355)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0070355"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "mirabegron extended-release tablets mirabegron granules two different products substitutable milligram-per-milligram basis . select recommended product ( mirabegron extended-release tablets mirabegron granules ) based indication patient 's weight . oab adults recommended starting dose mirabegron extended-release tablets 25 mg orally daily . ( 2.2 ) 4 8 weeks , mirabegron extended-release tablets dose may increased 50 mg orally daily . ( 2.2 ) ndo pediatric patients 3 years older pediatric patients weighing 35 kg : mirabegron extended-release tablets : recommended starting mirabegron extended-release tablets 25 mg orally daily . 4 8 weeks , mirabegron extended-release tablets dose may increased 50 mg orally daily . ( 2.3 ) adult pediatric patients patients renal hepatic impairment : refer full prescribing information recommended . ( 2.4 , 2.5 ) mirabegron extended-release tablets : adult patients : swallow mirabegron extended-release tablets whole water . chew , divide , crush . take without food . ( 2.7 ) pediatric patients : swallow mirabegron extended-release tablets whole water . chew , divide , crush . take food . ( 2.7 )",
        "doid_entities": [
            {
                "text": "oab (DOID:0070355)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0070355"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "mirabegron extended-release tablets , 50mg yellow colored , oval shaped , biconvex , film-coated tablets debossed `` 1160 `` one side plain side supplied follows : ndc : 70518-4304-00 packaging : 90 1 bottle plastic store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "mirabegron extended-release tablets contraindicated patients known hypersensitivity mirabegron inactive ingredients tablet [ ( 6.1 , 6.2 ) ] .",
    "indications_original": "Mirabegron extended-release tablets are a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 )",
    "contraindications_original": "Mirabegron extended-release tablets and Mirabegron Granules are two different products and they are not substitutable on a milligram-per-milligram basis. Select the recommended product (Mirabegron extended-release tablets and Mirabegron Granules) based on the indication and patient's weight. OAB in Adults The recommended starting dose of mirabegron extended-release tablets is 25 mg orally once daily. ( 2.2 ) After 4 to 8 weeks, the mirabegron extended-release tablets dose may be increased to 50 mg orally once daily. ( 2.2 ) NDO in Pediatric Patients 3 Years and Older Pediatric Patients weighing 35 kg or more: Use mirabegron extended-release tablets: The recommended starting dosage of mirabegron extended-release tablets is 25 mg orally once daily. After 4 to 8 weeks, the mirabegron extended-release tablets dose may be increased to 50 mg orally once daily. ( 2.3 ) Adult or Pediatric Patients Patients with Renal or Hepatic Impairment : Refer to the full prescribing information for recommended dosage. ( 2.4 , 2.5 ) Administration Mirabegron extended-release tablets: Adult patients: Swallow mirabegron extended-release tablets whole with water. Do not chew, divide, or crush. Take with or without food. ( 2.7 ) Pediatric patients: Swallow mirabegron extended-release tablets whole with water. Do not chew, divide, or crush. Take with food. ( 2.7 )",
    "warningsAndPrecautions_original": "Mirabegron extended-release tablets, 50mg are yellow colored, oval shaped, biconvex, film-coated tablets debossed with \"1160\" on one side and plain on other side and are supplied as follows:\n                  \n                  NDC: 70518-4304-00\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Mirabegron extended-release tablets are contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of the tablet\n \n  [see Adverse Reactions (\n  \n   6.1,\n  \n   6.2)].",
    "drug": [
        {
            "name": "Mirabegron",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_65349"
        }
    ]
}